Abstract:Abstract Background Antibody–drug conjugates (ADC) typically consist of a monoclonal antibody (mAbs) attached to a cytotoxic payload via a chemical linker. ADC development requires careful consideration of each of its key components and development strategy since each element has the potential to affect the final therapeutic efficacy and safety. One important characteristic of an ADC drug is the drug-to-antibody ratio (DAR). This ratio elucidates the number of drug molecules bound onto a single antibody. Based on the conjugation strategy, the number of drug molecules that are bound to a single antibody varies. Low-drug loading reduces the overall potency, whereas high-drug loading can have higher cytotoxic effects but increased side-effects and altered pharmacokinetics (PK). As such, appropriate selection of conjugation strategy can affect the homogeneity of ADCs and resulting effectiveness. To increase the efficacy of ADCs, site-specific conjugation technologies, including engineered cysteine residues, unnatural amino acids, or enzymatic conjugation through glycosyltransferases, have been applied to obtain more homogeneous ADCs. This has proven to be clinically effective by improving ADC pharmacokinetics and therapeutic index. Furthermore, the increased control over conjugation site reduces the overall hydrophobicity of the linker–payload, preventing unintended payload release in blood. AGLink ADC site-specific conjugation kits were used to perform site-specific conjugation. The AGLink technology utilizes an enzymatic modification method (one-pot process) to reduce antibody N-glycans by fucosylation and enable site-specific and controllable conjugation. After conjugation, the resulting ADCs were evaluated for ADC homogeneity, immunoreactivity, and cytotoxicity. Methods and Results AGLink ADC site-specific conjugation were used and based on the conjugation platform YTConjuTM. To characterize the efficacy of AGLink, Trastuzumab and MMAE were used. N-glycans were identified to be at the asparagine 297 (N297) position of the CH2 domain on each heavy chain Fc fragment. The N-glycans were reduced to form reactive sites linked with payloads through glycosylation. The resulting glycosylation is predominantly composed of varied amounts of N-acetylglucosamine, fucose, galactose, mannose and N-acetylneuraminic acid (sialic acid) residues, which are assembled in different complex-type biantennary structures. The resulting ADCs (Trastuzumab-MMAE) with different DARs (2 or 4) were developed and characterized through varying studies. Conclusion Site-specific modifications are beginning to be used more frequently to meet the rapidly evolving applications of ADCs. Of these modification methods, we see that glycoengineering has been demonstrated as a useful approach for site-specific antibody conjugation methods. The AGLink site-specific conjugation kit utilizes glycoengineering by performing an enzymatic modification method of IgG Fc glycans to perform conjugation. AGLink does not require any prior engineering of the amino acid sequence, and results in stable antibody conjugates with minimal variation between batches. As a result, the AGLink technology used in the conjugation kit offers a unique site-specific conjugation method with potential applications for preclinical development of MMAE-ADCs.

Transglutaminase-based Antibody-Drug Conjugation: Antibody Site-Specific Mutation and Identification

Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.

Enhancing Substrate Specificity of Microbial Transglutaminase for Precise Nanobody Labeling

Investigation of High Molecular Weight Size Variant Formation in Antibody-Drug Conjugates: Microbial Transglutaminase-Mediated Crosslinking

Identification of a novel transasparaginase activity of Bacillus Subtilis (bTG) for sequence-specific bioconjugation.

Single-step Enzymatic Glycoengineering for the Construction of Antibody-cell Conjugates

Identification of a Novel Transasparaginase Activity of Bacillus subtilis (bTG) for Sequence-Specific Bioconjugation

Antibody conjugation via one and two C-terminal selenocysteines

Preparation of Antigastric Cancer Monoclonal Antibody-Mitomycin-C Conjugate Via A New Type of Conjugation Method

Site‐specific modification of native IgGs with flexible drug‐load

ACCELERATING THE DEVELOPMENT OF NOVEL ANTIBODY-DRUG CONJUGATES THROUGH SITE-SPECIFIC CONJUGATION METHODS

A Switchable Site-Specific Antibody Conjugate.

Light Chain Q166C Mutation Permits One‐step Site Specific Conjugation on Monoclonal Antibodies

An Unexpected Single-step Glycosylation Enables the Construction of Antibody-Biomacromolecule Conjugates As Therapeutics

A Single-Step Chemoenzymatic Reaction for the Construction of Antibody-Cell Conjugates

Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody-Drug Conjugates

Site-Specific Modification of Single Domain Antibodies by Enzyme-Immobilized Magnetic Beads

A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies

Production of site-specific antibody–drug conjugates using optimized non-natural amino acids in a cell-free expression system

Conjugation Site Analysis of Antibody-Drug-conjugates (adcs) by Signature Ion Fingerprinting and Normalized Area Quantitation Approach Using Nano-Liquid Chromatography Coupled to High Resolution Mass Spectrometry.